Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2014
Filed with the SEC on Jul 3, 2014 and accepted by EDGAR at Jul 3, 2014, 20:04 ET.
Management's discussion and analysis
As filed, 29,321 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward Looking Statements
This Form 10-Q, press releases and certain information provided periodically in writing or orally by the Company’s officers or its agents may contain statements which constitute “forward-looking statements”. The terms “Cryo-Cell International, Inc.,” “Cryo-Cell,” “Company,” “we,” “our” and “us” refer to Cryo-Cell International, Inc. The words “expect,” “anticipate,” “believe,” “goal,” “strategy,” “plan,” “intend,” “estimate” and similar expressions and variations thereof, if used, are intended to specifically identify forward-looking statements. Those statements appear in a number of places in this Form 10-Q and in other places, and include statements regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things:
(i) our future performance and operating results;
(ii) our future operating plans;
(iii) our liquidity and capital resources; and
(iv) our financial condition, accounting policies and management judgments.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The factors that might cause such differences include:
(i) any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities;
(ii) any increased competition in our business including increasing competition from public cord blood banks particularly in overseas markets but also in the U.S.;
(iii) any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees;
(iv) any new services relating to other types of stem cells that have not yet been offered commercially, and there is no assurance that other stem cell services will be launched or will gain market acceptance;
(v) any adverse impacts on revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our facility and costs relating to the commercial launch of the placental stem cell service offering or any other new types of stem cells;
(vi) any unique risks posed by our international activities, including but not limited to local business laws or practices that diminish our affiliates’ ability to effectively compete in their local markets;
(vii) any technological or medical breakthroughs that would render our business of stem cell preservation obsolete;
(viii) any material failure or malfunction in our storage facilities; or any natural disaster or act of terrorism that adversely affects stored specimens;
(ix) any adverse results to our prospects, financial condition or reputation arising from any material failure or compromise of our information systems;
(x) the costs associated with defending or prosecuting litigation matters, particularly including litigation related to intellectual property, and any material adverse result from such matters;
(xi) the success of our licensing agreements and their ability to provide us with royalty fees;
(xii) any difficulties and increased expense in enforcing our international licensing agreements;
(xiii) any adverse performance by or relations with any of our licensees;
(xiv) any inability to enter into new licensing arrangements including arrangements with non-refundable upfront fees;
(xv) any inability to realize cost savings as a result of recent acquisitions;
(xvi) any inability to realize a return on an investment;
(xvii) any increased U.S. income tax expense as a result of inability to utilize or exhaustion of net operating losses;
(xviii) any adverse impact on our revenues and operating margins as a result of discounting of our services in order to generate new business in tough economic times where consumers are selective with discretionary spending;
(xix) the success of our global expansion initiatives;
(xx) our actual future ownership stake in future therapies emerging from our collaborative research partnerships;
(xxi) the ability of our reproductive tissue storage services to generate new revenues;
(xxii) our ability to minimize our future costs related to R&D initiatives and collaborations and the success of such initiatives and collaborations;
(xxiii) any inability to successfully identify and consummate strategic acquisitions;
(xxiv) any inability to realize benefits from any strategic acquisitions;
(xxv) the costs associated with proxy contests and its impact on our business and
(xxvi) other factors many of which are beyond our control.
We undertake no obligation to publicly update or revise the forward-looking statements made in this Form 10-Q to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. Cryo-Cell International, Inc. undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed by the Company and any Current Reports on Form 8-K filed by the Company.
Overview
The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use. The Company’s principal sources of revenues are service fees for cord blood processing and preservation for new customers and recurring annual storage fees. Effective February 1, 2012, the Company charges fees of $2,074 to new clients for the collection kit, processing and testing and return medical courier service, with discounts in the case of multiple children from the same family and in other circumstances. The Company currently charges an annual storage fee of $125 for new clients; storage fees for existing customers depend on the contracts with such customers. The Company also offers a one-time payment plan, where the client is charged $3,949 less discounts in the case of multiple children from the same family and in other circumstances. The one-time plan includes the collection kit, processing and testing, return medical courier service and 21 years of pre-paid storage fees. The Company also receives other income from licensing fees and royalties from global affiliates.
In August 2011, there was a change in control of the board of directors. Upon gaining control of the Company, new management conducted a thorough review of the Company’s operations and determined that the best use of corporate resources was to refocus on the Company’s umbilical cord blood and cord tissue business while continuing to evaluate the menstrual stem cell technology. The Company recently decided to cease offering a commercial menstrual stem cell service for the time being due to a lack of market acceptance.
During the six months ended May 31, 2014, total revenue increased 8% as compared to the same period in 2013. The Company reported net income of approximately $613,000 or $0.06 per basic common share for the six months ended May 31, 2014 compared to net income of approximately $350 or $0.00 per basic common share for the same period in 2013. The net income for the six months ended May 31, 2014 principally resulted from the 8% increase in revenues which was partially offset by a 4% increase in selling, general and administrative expenses and a 6% increase in cost of sales.
At May 31, 2014, the Company had cash and cash equivalents of $3,403,716. The Company’s cash decreased by approximately $521,000 during the first six months of fiscal 2014, primarily as a result of approximately $1,407,000 used for the stock repurchase plan pursuant to which the Company repurchased 636,531 shares of the Company’s common stock during the six months ended May 31, 2014 which was offset by approximately $362,000 by cash provided by operations and approximately $764,000 transferred from the trust (See Note 6). As of May 31, 2014, the Company had no long-term indebtedness.
Consistent with its fiduciary duties, the board of directors and management has reviewed and will continue to review strategic options and opportunities for the Company, in order to maximize shareholder value. These options may include strategic mergers or acquisitions, a deregistration of the Company’s common stock under the Securities Exchange Act of 1934 or a going-private transaction. However, no such transactions or actions are contemplated at this time.
The Company has not had a third party conduct a physical inventory count of all specimens stored; however, the Company from time to time will perform a physical inventory count of specimens stored to ensure that all records are accurate.
Results of Operations - Six Month Period Ended May 31, 2014 Compared to the Six Month Period Ended May 31, 2013
Revenues. Revenues for the six months ended May 31, 2014 were $10,213,328 as compared to $9,458,650 for the same period in 2013. The increase in revenue was primarily attributable to a 3% increase in processing and storage fees and by a 74% increase in licensee income.
Processing and Storage Fees. The increase in processing and storage fee revenue is primarily attributable to an 8% increase in recurring annual storage fee revenue. The Company had a 18% decrease in the number of new cord blood specimens processed in the first six months of fiscal 2014 versus the same period in 2013. The decrease in new cord blood specimens is primarily attributable to the 51% decrease in the number of new specimens from the Company’s international affiliates, mainly Ecuador. In August 2013, the Company was notified that its affiliate in Ecuador was closed by the National Institute of Organic Donation (INDOT).
Licensee Income. Licensee income for the six months ended May 31, 2014, was $1,132,662 as compared to $651,764 for the 2013 period. Licensee income for the six months ended May 31, 2014 consists of $794,000 related to Mexico which is a result of Mexico paying off the remaining balance due under the amendment during the first quarter of fiscal 2014. The remaining licensee income consists of royalty income earned on the processing and storage of specimens in geographical areas where the Company has license agreements. Mexico has no other continuing obligations to the Company for royalties or other license payments and the agreement is terminated. The amendment is expected to result in a reduction of licensee income in future periods. Licensee income for the six months ended May 31, 2013 consists of royalty income earned on the processing and storage of specimens in geographical areas where the Company has license agreements.
Cost of Sales. Cost of sales for the six months ended May 31, 2014 was $2,824,066 as compared to $2,654,837 for the same period in 2013, representing a 6% increase. Cost of sales was 28% of revenues for the six months ended May 31, 2014 and 28% for the six months ended May 31, 2013. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of approximately $103,000 and $104,000 for the six months ended May 31, 2014 and 2013, respectively.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended May 31, 2014 were $5,875,863 as compared to $5,653,246 for the 2013 period representing a 4% increase. These expenses are primarily comprised of expenses for consumer advertising, salaries and wages for personnel and professional fees. Included in selling, general and administrative expenses is approximately $354,000 in legal fees during the first quarter of fiscal 2014 related to a shareholder derivative complaint filed in November 2013, which is excluded from the Company’s directors and officer’s insurance policy.
Abandonment of Patents. During the six months ended May 31, 2014 and May 31, 2013, management decided to discontinue pursuing certain patents and trademarks resulting in a write-off of approximately $26,000 and $379,000, respectively, for abandoned patents and trademarks related to the Company’s menstrual stem cell technology which is reflected as abandonment of patents in the accompanying consolidated statement of operations. The impact to future operations is considered immaterial and is not expected to impact the Company’s core operations.
Research, Development and Related Engineering Expenses. Research, development and related engineering expenses for the six months ended May 31, 2014 were $32,691 as compared to $17,986 for the 2013 period representing an 82% increase. The expenses for each period primarily relate to implementation enhancements of the Company’s cord tissue service.
Depreciation and Amortization. Depreciation and amortization (not included in Cost of Sales) for the six months ended May 31, 2014 was $88,204 compared to $101,855 for the 2013 period.
Interest Expense. Interest expense during the six months ended May 31, 2014, was $526,860 compared to $512,749 during the comparable period in 2013. Interest expense is mainly comprised of amounts due to the parties to the Company’s revenue sharing agreements (“RSAs”) based on the Company’s storage revenue
Equity in Losses of Affiliate. Equity in losses of affiliate was $189,651 for the six months ended May 31, 2014, compared to $76,900 for the 2013 period. Equity in losses of affiliate for the six months ended May 31, 2014 consists of $112,500 related to additional investments made by the Company into Saneron and $77,151 related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees. Equity in losses of affiliate for the six months ended May 31, 2013, consists of $76,900 which solely related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.
Income Taxes. Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.
The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recorded $72,702 and $85,118 for the six months ended May 31, 2014 and May 31, 2013, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of operations.
The Company did not record U.S. income tax expense or benefit during the six months ended May 31, 2014 and for the same period in 2013, due to the utilization of net operating losses and foreign tax credit carryforwards, which were not previously benefited in the Company’s financial statements.
Results of Operations - Three Month Period Ended May 31, 2014 Compared to the Three Month Period Ended May 31, 2013
Revenues. Revenues for the three months ended May 31, 2014 were $4,892,846 as compared to $4,858,563 for the same period in 2013. The increase in revenue was primarily attributable to a 4% increase in processing and storage fees offset by a 48% decrease in licensee income. The decrease in licensee income is due to Mexico paying the balance due per the amendment dated August 19, 2011 during the first quarter 2014. Mexico has no other continuing obligations to the Company for royalties or other license payments and the agreement is terminated
Processing and Storage Fees. The increase in processing and storage fee revenue is primarily attributable to an 8% increase in recurring annual storage fee revenue. The Company also had a 14% decrease in the number of new cord blood specimens processed for three months ended May 31, 2014 versus the same period in 2013. The decrease in new cord blood specimens is primarily attributable to a 46% decrease in the number of new specimens from the Company’s international affiliates, mainly Ecuador.
Licensee Income. Licensee income for the three months ended May 31, 2014, was $169,411 as compared to $328,230 for the 2013 period. Licensee income for the three months ended May 31, 2014 and May 31, 2013, consisted of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements
Cost of Sales. Cost of sales for the three months ended May 31, 2014 was $1,489,705 as compared to $1,375,024 for the same period in 2013, representing an 8% increase. Cost of sales was 30% of revenues for the three months ended May 31, 2014 and 28% for the three months ended May 31, 2013. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of approximately $52,000 and $52,000 for the three months ended May 31, 2014 and 2013, respectively. The increase in cost of sales during the three months ended May 31, 2014 compared to the 2013 period is primarily attributable to the increase in laboratory costs associated with the Company’s new superior processing technology.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended May 31, 2014 were $2,753,140 as compared to $2,957,968 for the 2013 period representing a 7% decrease. These expenses are primarily comprised of expenses for consumer advertising, salaries and wages for personnel and professional fees. The decrease in selling, general and administrative expenses was primarily due to a decrease of approximately $175,000 in legal fees.
Abandonment of Patents. During the three months ended May 31, 2014 and May 31, 2013 management decided to discontinue pursuing certain patents and trademarks resulting in a write-off of approximately $26,000 and $379,000, respectively, for abandoned patents and trademarks related to the Company’s menstrual stem cell technology which is reflected as abandonment of patents in the accompanying consolidated statement of operations The impact to future operations is immaterial and it will not impact the Company’s core operations.
Research, Development and Related Engineering Expenses. Research, development and related engineering expenses for the three months ended May 31, 2014 were $18,323 as compared to $7,065 for the 2013 period. The expenses for each period primarily relate to implementation enhancements of the Company’s cord tissue service.
Depreciation and Amortization. Depreciation and amortization (not included in Cost of Sales) for the three months ended May 31, 2014 was $43,699 compared to $50,841 for the 2013 period.
Interest Expense. Interest expense during the three months ended May 31, 2014, was $252,544 compared to $262,211 during the comparable period in 2013. Interest expense is mainly comprised of payments made to the other parties to the Company’s RSAs based on the Company’s storage revenue.
Equity in Losses of Affiliate. Equity in losses of affiliate was $76,076 for the three months ended May 31, 2014, compared to $38,450 for the 2013 period. Equity in losses of affiliate for the three months ended May 31, 2014 consists of $37,500 related to additional investments made by the Company into Saneron and $38,576 related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees. Equity in losses of affiliate for the three months ended May 31, 2013 consists solely of amounts related to compensation expense for stock option awards that were granted by Saneron to certain consultants and employees.
Income Taxes. Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company must project future levels of taxable income. This assessment requires significant judgment. The Company examined the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.
The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The Company recorded $25,411 and $42,794 for the three months ended May 31, 2014 and 2013, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of operations. The decrease in foreign tax expense is attributable to the increase in royalties recognized during the period ended May 31, 2014 compared to May 31, 2013.
The Company did not record U.S. income tax expense or benefit during the three months ended May 31, 2014 and for the same period in 2013, due to the utilization of net operating losses and foreign tax credit carryforwards, which were previously reserved through valuation allowances in the Company’s financial statements.
Liquidity and Capital Resources
Through May 31, 2014, the Company’s principal source of cash has been from sales of its umbilical cord blood program to customers and royalties from licensees. The Company does not expect a change in its principal source of cash flow.
At May 31, 2014, the Company had cash and cash equivalents of $3,403,716 as compared to $3,925,156 at November 30, 2013. The decrease in cash and cash equivalents during the six months ended May 31, 2014 was primarily attributable to the following:
Net cash provided by operating activities for the six months ended May 31, 2014 was $361,757 principally due to an 8% increase in revenues which was partially offset by a 4% increase in selling, general and administrative expenses and a 6% increase in cost of sales.
Net cash provided by operating activities for the six months ended May 31, 2013 was $1,089,396 principally due to a 10% increase in revenues and a 24% decrease in selling, general and administrative expenses. This was partially offset by a 19% increase in cost of sales.
Net cash provided by investing activities for the six months ended May 31, 2014 was $475,416, which was primarily attributable to the transfer of $764,098 from the trust which was offset by $176,182 of purchases of property and equipment and marketable securities and the investment of $112,500 into Saneron (see above).
Net cash used in investing activities for the six months ended May 31, 2013 was $206,173, which was primarily attributable to the purchases of property and equipment.
Net cash used in financing activities for the six months ended May 31, 2014 was $1,358,613, which was primarily attributable the stock repurchase plan pursuant to which the Company has repurchased 636,531 shares of the Company’s common stock for approximately $1,407,000.
Net cash used in financing activities for the six months ended May 31, 2013 was $656,141, which was primarily attributable the stock repurchase plan pursuant to which the Company has repurchased 300,391 shares of the Company’s common stock for approximately $668,000.
The Company does not have a line of credit.
The Company anticipates making discretionary capital expenditures of approximately $500,000 over the next twelve months for software enhancements and purchases of property and equipment. The Company anticipates funding future property and equipment purchases with cash-on-hand and cash flows from future operations.
The Company anticipates that its cash and cash equivalents, marketable securities and cash flows from future operations will be sufficient to fund its known cash needs for at least the next 12 months. Cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services, and managing discretionary expenses. If expected increases in revenues are not realized, or if expenses are higher than anticipated, the Company may be required to reduce or defer cash expenditures or otherwise manage its cash resources during the next 12 months so that they are sufficient to meet the Company’s cash needs for that period. In addition, the Company may consider seeking equity or debt financing if deemed appropriate for its plan of operations, and if such financing can be obtained on acceptable terms. There is no assurance that any reductions in expenditures, if necessary, will not have an adverse effect on the Company’s business operations, including sales activities and the development of new services and technology.
Critical Accounting Policies
This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures of contingent assets and liabilities. For a full discussion of our accounting policies please refer to Note 1 to the Consolidated Financial Statements included in our 2013 Annual Report on Form 10-K filed with the SEC. Our most critical accounting policies and estimates include: recognition of revenue and the related allowance for doubtful accounts, stock-based compensation, income taxes and license and revenue sharing agreements. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, historical experience and other factors that we believe are reasonable based on the circumstances, the results of which form our management’s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2013 Annual Report on Form 10-K.
Recently Issued Accounting Pronouncements
In July 2013, the FASB issued Accounting Standards Update No. 2013-11, *Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“*ASU 2013-11”). This update will require companies to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless certain conditions exist. ASU 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The Company adopted ASU 2013-11 in the first quarter of 2014. The adoption of ASU 2013-11 had no impact on the Company’s consolidated financial statements or on its financial condition.
In September 2013, the Internal Revenue Service issued final regulations governing the income tax treatment of the acquisition, disposition and repair of tangible property. The regulations are effective for taxable years beginning on or after January 1, 2014. The Company does not expect these new regulations to have a material impact on the financial statements.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Controls and procedures
As filed, 3,300 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Based on their most recent review, as of the end of the period covered by this report, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures are effective, and that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are effective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal controls over financial reporting during the three months ended May 31, 2014 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Limitations on the Effectiveness of Controls
Our management, including our co-CEOs and CFO, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.
The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
CEO and CFO Certifications
Appearing as exhibits 31.1, 31.2 and 31.3 to this report there are Certifications of the Co-CEOs and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report is the information concerning the evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-03-01 to 2014-05-31 | $4.9m | us-gaap:Revenues |
| Revenue | 6 months2013-12-01 to 2014-05-31 | $10.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-03-01 to 2014-05-31 | $1.5m | us-gaap:CostOfServices |
| Cost of revenue | 6 months2013-12-01 to 2014-05-31 | $2.8m | us-gaap:CostOfServices |
| Research and development | 3 months2014-03-01 to 2014-05-31 | $18.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2013-12-01 to 2014-05-31 | $32.7k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-03-01 to 2014-05-31 | $2.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2013-12-01 to 2014-05-31 | $5.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-03-01 to 2014-05-31 | $562.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-12-01 to 2014-05-31 | $1.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-03-01 to 2014-05-31 | $252.5k | us-gaap:InterestExpense |
| Interest expense | 6 months2013-12-01 to 2014-05-31 | $526.9k | us-gaap:InterestExpense |
| Income tax | 3 months2014-03-01 to 2014-05-31 | $25.4k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2013-12-01 to 2014-05-31 | $72.7k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-03-01 to 2014-05-31 | $215.8k | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-12-01 to 2014-05-31 | $612.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-03-01 to 2014-05-31 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2013-12-01 to 2014-05-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-03-01 to 2014-05-31 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2013-12-01 to 2014-05-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-03-01 to 2014-05-31 | 10,406,607 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2013-12-01 to 2014-05-31 | 10,595,590 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2013-12-01 to 2014-05-31 | $361.8k | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months2013-12-01 to 2014-05-31 | $73.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2013-12-01 to 2014-05-31 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2014-05-31 | $3.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-05-31 | $8.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-05-31 | $10.3m | us-gaap:Assets |
| Current liabilities | At period end2014-05-31 | $8.8m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2014-05-31 | $2.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2014-05-31 | −$9.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-14-260800. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.